Description: AccuStem Sciences, Inc. operates as a life sciences company focusing on improving outcomes for patients with cancer. It develops StemPrintER technology, a multi-gene prognostic assay to predict the risk of recurrence of Endocrine receptor-positive /HER2- breast cancer; and Spare, a derivative of StemPrintER that combines StemPrintER with two clinical markers. The company is based in New York, New York.
Home Page: accustem.com
5 Penn Plaza
New York,
NY
10001
United States
Phone:
Officers
| Name | Title |
|---|---|
| Mr. Gabriele Marco Antonio Cerrone M.B.A. | Executive Chairman of the Board |
| Ms. Wendy E. Blosser | CEO & Director |
| Mr. Joe Flanagan | Chief Business Officer |
| Ms. Keeren Shah | Chief Financial Officer |
Exchange: OTCQB
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 3 |